Keywords: Forest Labs, Cari[razzine, USA, FDA, Schizophrenia, Bipolar disease, Bystolic, Patent settlement, Alkerm, IndChemie, Torrent

Forest Labs files NDA for cariprazine for schizophrenia and bipolar indications; patent settlements

Article | 29 November 2012

Print This

Forest Laboratories (NYSE: FRX) has submitted a New Drug Application to the US Food and Drug Administration for cariprazine, a ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in